Antibe Therapeutics Inc. (TSE:ATE – Get Free Report) traded up 13.5% during trading on Monday . The company traded as high as C$0.35 and last traded at C$0.30. 167,044 shares traded hands during trading, an increase of 23% from the average session volume of 135,475 shares. The stock had previously closed at C$0.26.
Antibe Therapeutics Stock Performance
The company has a market capitalization of C$15.64 million, a P/E ratio of -0.84 and a beta of 0.19. The company has a fifty day moving average price of C$0.30. The company has a quick ratio of 9.58, a current ratio of 10.06 and a debt-to-equity ratio of 0.29.
About Antibe Therapeutics
Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).
Read More
- Five stocks we like better than Antibe Therapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- ESG Stocks, What Investors Should Know
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Investing In Automotive Stocks
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
